In a sign of a biotech rebound, Massachusetts-headquartered biopharma companies received $7.89 billion in venture capital (VC) funding, marking the first year-over-year increase since the pandemic, according to a newly released year-end report from biopharma member organization MassBio. For the first time ever, the report also found that private biopharma companies based in Boston collected more venture […]

Eli Lilly has agreed to acquire Scorpion’s PI3Kα inhibitor STX-478 which is currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. STX-478 could represent the next generation of PI3Kα targeting agents by selectively targeting the pathway in cancerous but not healthy cells, thus overcoming a key limitation […]

IDRx, a Boston-based, clinical-stage biopharm dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST) is being acquired by GSK. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule IDRX-42 being developed as a first- […]

Cambridge-based gene editing company Editas Medicine is planning a critical pivot to optimize its cost structure, extend its cash runway into Q2 2027, and position the company to accelerate its intent to achieve in vivo human proof of concept in approximately two years. “Recent scientific breakthroughs by the Editas team have convinced us that the timelines around […]

Watertown-based Neumora Therapeutics, a clinical-stage biopharm with a pipeline consisting of seven clinical and pre-clinical brain disease programs, has announced disappointing results from a Phase 3 study of navacaprant for the treatment of major depressive disorder (MDD). The study did not demonstrate a statistically significant improvement in MDD study participants overall. “We are disappointed by […]